Pharmacologic profile of perphenazine's metabolites

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 181-187

  Sweet, Robert A ^a,c   Pollock, Bruce G ^a   Mulsant, Benoit H ^a   Rosen, Jules ^a   Sorisio, Denise ^a   Kirshner, Margaret ^a   Henteleff, Ruth ^a   Demichele, Mary Ann A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Carlow University   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYPERPHENAZINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; N DEALKYLPERPHENAZINE; PERPHENAZINE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BINDING COMPETITION; DEMENTIA; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; BRAIN; CELL LINE, TRANSFORMED; CYTOCHROME P-450 CYP2D6; DEMENTIA; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERPHENAZINE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN;

EID: 0034034596     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00010     Document Type: Article

References (28)

1. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-2.
2. Ayd FJ Jr. Drug-induced extrapyramidal reactions: their clinical manifestations and treatment with Akineton. Psychosomatics 1960;1:143-50.
3. Sweet RA, Mulsant BH, Pollock BG, Rosen J, Altieri LP. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer type. Am J Geriatr Psychiatry 1996;4:311-9.
4. Casey DE. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berl) 1993;112:855-359.
5. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
6. Bolvig-Hansen L, Larsen N. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berl) 1985;87:16-9.
7. Mazure CM, Nelson JC, Jatlow PI, Kincare P, Bowers MB. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. J Clin Psychiatry 1990; 51:330-4.
8. 2 receptors. Psychopharmacology (Berl) 1993;112:340-854.
9. Meltzer HY. Serotonin-dopamine interactions and atypical antipsychotic drugs. Psychiatr Ann 1993;23:193-200.
10. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57[suppl 11]: 4-11.
11. Bolvig Hansen L, Elley J, Rosted Christensen T, Larsen NE, Naestoft J, Hvidberg EF. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 1979;7:75-80.
12. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Altieri LP, Perel JM. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995;31:327-31.
13. Zubenko GS, Rosen J, Sweet RA, Mulsant BH, Rifai AH. Impact of psychiatric hospitalization on behavioral complications of Alzheimer's disease. Am J Psychiatry 1992;149:1484-91.
14. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
15. Sweet RA, Akil M, Mulsant BH, Ulrich R, Pasternak RE, Zubenko GS. Spontaneous extrapyramidal symptoms in elderly psychiatric inpatients: a comparison of Alzheimer's disease, major depressive disorder and psychotic disorder. J Neuropsychiatry Clin Neurosci 1998;10:68-77.
16. Foglia JP, Sorisio D, Kirshner MA, Mulsant BH, Perel JM. Quantitative determination of perphenazine and its metabolites in plasma by high-performance liquid chromatography and coulometric detection. J Chromatogr 1995;668:291-7.
17. Motulsky HJ, Stannard P, Neubig R, Platt M, Pilkington J, Searle P. GraphPad Prism user's guide. San Diego: GraphPad Software, Inc., 1976.
18. Bymaster FP. In vitro and in vivo biochemistry of olanzapine. J Clin Psychiatry Monogr 1997;15:10-2.
19. Bolvig-Hansen L, Larsen N, Gulmann N. Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berl) 1982;78:112-5.
20. Baldessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge, MA: Harvard University Press, 1985.
21. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harv Rev Psychiatry 1995;2:327-35.
22. Mulsant BH, Mazumdar S, Pollock BG, Sweet RA, Rosen J, Lo K. Methodological issues in characterizing treatment response in demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1996;12:537-47.
23. Mazure CM, Nelson JC, Jatlow PI, Bowers MB Jr. Acute neuroleptic treatment in elderly patients without dementia. Am J Geriatr Psychiatry 1998;6:221-9.
24. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-8.
25. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Williams AC, Spurr NK, Wolfe CR. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-7.
26. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation gene in Parkinson's disease. Lancet 1992;339:1017-8.
27. Gilham D, Cairns W, Paine M, Poulsom R, Roberts GC, Wolf CR. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-25.
28. Pollock BG, Perel JM, Altieri LP, Kirshner M, Fasiczka AL, Houck PR, Reynolds CF 3d. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992;28:163-8.